This is the authors' abstract. We don't add key points for this paper.
CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea, NSC-79037), was used to treat 141 evaluable patients with a variety of advanced malignancies, 56% of whom had not received prior chemotherapy. Patients with an adequate bone marrow reserve received 130 mg/m2 as the initial dose and those with an impaired reserve received 100 mg/m2. Therapy was repeated every 6 weeks and the dosage modified according to the hematologic toxicity. Responses greater than 50% reduction in tumor size were noted in 26 patients; stable disease or reduction in tumor size of less than 50% was observed in 21 patients. The well-differentiated adenocarcinomas and squamous cell tumors appeared to be least sensitive to CCNU. Bone marrow depression was the major dose-limiting factor. Without adequate antiemetic therapy, all patients would have had nausea and vomiting. Hepatocellular toxicity was noted in two patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hoogstraten et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: